FMC Corp

FMC’s stock plunged in pre-market trading after the company’s adjusted operating result in the second quarter surprised positively, but it confirmed its full-year outlook. Analysts at JPMorgan and UBS warned this could lead to lower estimates for the second half of the year. Bernstein also criticized weaker treatment numbers in the U.S.; the stock lost more than eight percent on Tradegate. » Altro su de.investing.com

FMC shares fell to a 52-week low of $10.55, down 74.28% year‑over‑year. The company carries $4.66 billion in debt and a negative free cash flow (-$219.8 million). Tessenderlo is investing $400 million for a 20% stake to help reduce debt; FMC is also selling a parcel in Delaware for about $114 million and has filed an EPA registration dossier for the herbicide Rimisoxafen. BMO Capital reiterates a "Market Perform" rating, citing planned asset sales and the 2026 outlook. » Altro su de.investing.com

Exane BNP has downgraded FMC from “Neutral” to “Underperform”, after which the stock fell about 2.2% to just under €43. Analyst Hugo Solvet expects persistently lower treatment volumes in the US dialysis market and points to lowered consensus estimates despite share gains year-to-date. The downgrade for now ends the recovery following the recent high reached in November. » Altro su de.investing.com